Photo by nci from unsplash
Over the past decade, the survival of patients with multiple myeloma (MM) has dramatically improved. This remarkable change is largely due to an increase in the anti-myeloma armamentarium, including next… Click to show full abstract
Over the past decade, the survival of patients with multiple myeloma (MM) has dramatically improved. This remarkable change is largely due to an increase in the anti-myeloma armamentarium, including next generation proteasome inhibitors (carfilzomib, ixazomib), next generation immunomodulatory drugs
Keywords:
sustained response;
venetoclax therapy;
myeloma;
response venetoclax;
deep sustained;
therapy patient
Journal Title: Haematologica
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Haematologica
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!